hn.today

L'Oreal says weight loss drugs are impacting beauty and skin care sales

bbc.com8 points1 comments
Screenshot of L'Oreal says weight loss drugs are impacting beauty and skin care sales

L'Oreal's chief Nicolas Hieronimus says rising use of GLP-1 weight-loss drugs - originally developed for diabetes and sold as Ozempic, Wegovy and Mounjaro - has begun to reshape beauty consumption, particularly skincare. Rapid, drug-triggered weight loss suppresses appetite and can leave some people with loose or sagging skin, including around the face, prompting demand for targeted treatments. L'Oreal reported group sales rose 7.7% in the three months to September and says brands such as SkinCeuticals and Kiehl's have developed products designed to complement GLP-1-related skin changes.

The company is deepening its push into clinical aesthetics, increasing its stake in dermatology firm Galderma to 20% and collaborating on trials addressing post-weight-loss facial concerns. Galderma markets aesthetic injectables including Sculptra, which stimulates collagen, and Restylane fillers; both companies have been testing products specifically on GLP-1 users. A Galderma survey found most weight-loss drug users reported noticeable changes to facial appearance, underlining an emerging market for treatments that counteract perceived sagging or volume loss after rapid weight reduction.

Read on bbc.com1 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Other

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.